https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-bmb-101-update BiopharmaWatch en 2026-11-02T12:30:00.000Z Bright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies https://www.biopharmawatch.com/news/CRMD/cormedix-business-update-revenue-guidance BiopharmaWatch en 2026-11-02T12:30:00.000Z CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position https://www.biopharmawatch.com/news/CYTK/cytokinetics-hcms-scientific-sessions-2026 BiopharmaWatch en 2026-11-02T12:30:00.000Z Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026 https://www.biopharmawatch.com/news/RZLT/rezolute-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-02T12:30:00.000Z Rezolute to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/BWAY/brainsway-collaboration-mindful-health-solutions BiopharmaWatch en 2026-11-02T12:30:00.000Z BrainsWay Announces Strategic Collaboration with Mindful Health Solutions https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-q3-2026-update BiopharmaWatch en 2026-11-02T12:30:00.000Z Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026 https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-november-investor-conferences BiopharmaWatch en 2026-11-02T12:30:00.000Z Crescent Biopharma to Present at November Investor Conferences https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-q3-2026-financial-results-announcement BiopharmaWatch en 2026-11-02T12:15:00.000Z ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/KPTI/karyopharm-merger-ayrmid-future-plans BiopharmaWatch en 2026-11-02T12:10:00.000Z Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future https://www.biopharmawatch.com/news/QURE/uniqure-fda-acceptance-priority-review-huntingtons-disease BiopharmaWatch en 2026-11-02T12:05:00.000Z uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease https://www.biopharmawatch.com/news/YARW/yarrow-bioscience-investor-events-november-2026 BiopharmaWatch en 2026-11-02T12:00:00.000Z Yarrow Bioscience Announces Participation in November Investor Events https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-fda-ind-clearance-epetraborole-pv BiopharmaWatch en 2026-11-02T12:00:00.000Z AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-02T12:00:00.000Z Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress https://www.biopharmawatch.com/news/TLRY/tilray-brands-strengthens-canadian-cannabis-operations BiopharmaWatch en 2026-11-02T12:00:00.000Z Tilray Brands Announces Strategy to Strengthen Canadian Cannabis Operations and Drive Profitable Growth https://www.biopharmawatch.com/news/HROW/harrow-launches-harrowrx-platform BiopharmaWatch en 2026-11-02T12:00:00.000Z Harrow Launches HarrowRx Platform https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-q3-2026-results-call BiopharmaWatch en 2026-11-02T12:00:00.000Z Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/TLSA/tiziana-phase-2a-inform-ms-trial-results BiopharmaWatch en 2026-11-02T12:00:00.000Z Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis https://www.biopharmawatch.com/news/CLYM/climb-bio-guggenheim-healthcare-conference-2026 BiopharmaWatch en 2026-11-02T12:00:00.000Z Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/RAPP/rapport-closes-public-offerings-stock-notes BiopharmaWatch en 2026-11-02T12:00:00.000Z Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-investor-conferences-2026 BiopharmaWatch en 2026-11-02T12:00:00.000Z Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/KRYS/krystal-biotech-q3-2026-results BiopharmaWatch en 2026-11-02T12:00:00.000Z Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/CBLL/ceribell-launches-delirium-monitoring-solution BiopharmaWatch en 2026-11-02T12:00:00.000Z Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution https://www.biopharmawatch.com/news/KMDA/kamada-announces-q3-financial-results-call BiopharmaWatch en 2026-11-02T12:00:00.000Z Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-02T12:00:00.000Z Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ALVO/alvotech-investor-conferences-november-2026 BiopharmaWatch en 2026-11-02T12:00:00.000Z Alvotech to Present at Upcoming Investor Conferences in November https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-appoints-george-lederman BiopharmaWatch en 2026-11-02T12:00:00.000Z Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation https://www.biopharmawatch.com/news/KZIA/kazia-paxalisib-abstracts-sabcs-2026 BiopharmaWatch en 2026-11-02T12:00:00.000Z Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium https://www.biopharmawatch.com/news/CANF/can-fite-eurasian-patent-piclidenoson-lowe-syndrome BiopharmaWatch en 2026-11-02T12:00:00.000Z Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-et-900-program-mecasermin BiopharmaWatch en 2026-11-02T11:50:00.000Z Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms https://www.biopharmawatch.com/news/ACH/accendra-health-receivables-sale-program-extension-2029 BiopharmaWatch en 2026-11-02T11:45:00.000Z Accendra Health Announces Extension of $150 Million Receivables Sale Program To 2029 https://www.biopharmawatch.com/news/MRK/merck-new-data-hiv-glasgow-2026 BiopharmaWatch en 2026-11-02T11:45:00.000Z Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026 https://www.biopharmawatch.com/news/AGEN/agenus-unicorn-trial-results-colon-cancer BiopharmaWatch en 2026-11-02T11:42:00.000Z Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-third-quarter-results-2026 BiopharmaWatch en 2026-11-02T11:30:00.000Z IDEXX Laboratories Announces Third Quarter Results https://www.biopharmawatch.com/news/CMPS/compass-pathways-trd-survey-report BiopharmaWatch en 2026-11-02T11:30:00.000Z New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers https://www.biopharmawatch.com/news/RNA/atrium-therapeutics-atr-1072-prkag2-syndrome-data-presentation BiopharmaWatch en 2026-11-02T11:30:00.000Z Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026 https://www.biopharmawatch.com/news/IMUX/immunic-investor-conferences-november-2026 BiopharmaWatch en 2026-11-02T11:30:00.000Z Immunic to Participate in Investor Conferences in November https://www.biopharmawatch.com/news/OSUR/orasure-joins-world-coalition-sickle-cell-disease BiopharmaWatch en 2026-11-02T10:00:00.000Z OraSure Technologies Joins the World Coalition on Sickle Cell Disease to Advance Access to Earlier Diagnosis and Care https://www.biopharmawatch.com/news/VCRE/vicore-pharma-participate-guggenheim-stifel-conferences BiopharmaWatch en 2026-11-02T07:20:00.000Z Vicore Pharma to Participate in the Guggenheim Annual Healthcare Innovation Conference and the Stifel Healthcare Conference https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-11-02 BiopharmaWatch en 2026-11-02T07:16:14.403Z remibetadex NDA for Niemann-Pick Disease: Biotech Catalysts Nov 2, 2026 https://www.biopharmawatch.com/blog/Upcoming_Penny_Stock_Catalysts_in_June_2025_for_Biotech_and_Pharma_-_FDA_Calendar_and_PDUFA_Dates_to_Watch BiopharmaWatch en 2026-11-02T07:15:46.652Z Biotech Penny Stock Catalysts: FDA Calendar and PDUFA Dates for Small-Cap Pharma Stocks https://www.biopharmawatch.com/news/OCS/oculis-appoints-bjorn-tackenberg-cso-advance-neurology-innovation BiopharmaWatch en 2026-11-02T07:00:00.000Z Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation https://www.biopharmawatch.com/news/HCM/hutchmed-orpathys-tagrisso-regulatory-filings-europe-japan BiopharmaWatch en 2026-11-02T00:00:00.000Z HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan https://www.biopharmawatch.com/news/MESO/mesoblast-board-changes-november-2026 BiopharmaWatch en 2026-11-01T23:46:00.000Z Mesoblast Board Changes https://www.biopharmawatch.com/news/AVR/anteris-reports-duravr-thv-outcomes-embark-study BiopharmaWatch en 2026-11-01T19:59:00.000Z Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026 https://www.biopharmawatch.com/news/HTFL/ct-guided-pci-matches-ivus-outcomes-tct-2026 BiopharmaWatch en 2026-11-01T18:45:00.000Z TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients https://www.biopharmawatch.com/news/GEHC/ge-healthcare-allia-celeo-launch-tct-2026 BiopharmaWatch en 2026-11-01T17:35:00.000Z GE HealthCare debuts Allia Celeo, a ceiling-mounted interventional system designed for smooth procedural flow and AI-powered precision imaging https://www.biopharmawatch.com/news/ABT/abbott-tectonic-trial-sonicforce-results BiopharmaWatch en 2026-11-01T00:00:00.000Z Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System